Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Total Debt
Short-term and long-term borrowings combined.
Maze Therapeutics, Inc.NASDAQ: MAZE
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 137.1% from a year ago
Total debt stood at $61.22M at the end of Q1 FY2026, up 137.1% from a year earlier and up 162.7% from the prior quarter. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Total debt amounted to 14.6% of total assets at the end of Q1 FY2026, up 6.8 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +137.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 23.31M USD
- Year-over-year change
- -12.5%
- 3-year CAGR
- -10.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.31M | -12.5% |
| FY2024 | 2024-12-31 | 26.63M | -46.3% |
| FY2023 | 2023-12-31 | 49.62M | +54.8% |
| FY2022 | 2022-12-31 | 32.06M | — |
Total Debt vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +137.1% is the highest of 8, against a peer median of +9.3%.
- Total debt amounts to 14.6% of total assets for MAZE, versus a peer median of 21.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $696.47M USD | +79.4% | +22.8% | 21.4% | |
| Sep 2026 | $616.16M USD | +86.9% | -6.9% | 72.6% | |
| Mar 2026 | $208.26M USD | +34.3% | +79.7% | 41.3% | |
| Mar 2026 | $61.22M USD | +137.1% | -10.1% | 14.6% | |
| Dec 2025 | €59.4M EUR | +9.3% | +19.8% | 23.9% | |
SEPNSepterna, Inc. | Sep 2026 | $21.99M USD | -8.8% | +221.6% | 3.6% |
BIOABioAge Labs, Inc. | Mar 2026 | $4.03M USD | -60.9% | +31.1% | 1.0% |
| Mar 2026 | $212K USD | -32.9% | -20.0% | 0.4% | |
| Peer median (excluding MAZE) | — | +9.3% | +22.8% | 21.4% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.